» Articles » PMID: 23801600

Effectiveness of Intermittent Preventive Treatment with Sulfadoxine-pyrimethamine During Pregnancy on Maternal and Birth Outcomes in Machinga District, Malawi

Overview
Journal J Infect Dis
Date 2013 Jun 27
PMID 23801600
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae. Despite increasing prevalence of malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recommended for intermittent preventive treatment in pregnancy (IPTp).

Methods: Women without human immunodeficiency virus infection were enrolled upon delivery. Data on the number of SP doses received during pregnancy were recorded. The primary outcome was placental infection demonstrated by histologic analysis. Secondary outcomes included malaria parasitemia (in peripheral, placental, cord blood specimens) at delivery and composite birth outcome (small for gestational age, preterm delivery, or low birth weight). RESULTS.: Of 703 women enrolled, 22% received <2 SP doses. Receipt of ≥ 2 SP doses had no impact on histologically confirmed placental infection. IPTp-SP was associated with a dose-dependent protective effect on composite birth outcome in primigravidae, with an adjusted prevalence ratio of 0.50 (95% confidence interval [CI], .30-.82), 0.30 (95% CI, .19-.48), and 0.18 (95% CI, .05-.61) for 1, 2, and ≥ 3 doses, respectively, compared with 0 doses.

Conclusions: IPTp-SP did not reduce the frequency of placental infection but was associated with improved birth outcomes. Few women received no SP, so the true effect of IPTp-SP may be underestimated. Malawian pregnant women should continue to receive IPTp-SP, but alternative strategies and antimalarials for preventing malaria during pregnancy should be investigated.

Citing Articles

Uptake and Effectiveness of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine during Pregnancy in Africa: A Scoping Review.

Berchie G, Doe P, Azu T, Agyeiwaa J, Owusu G, Boso C Diseases. 2024; 12(9).

PMID: 39329872 PMC: 11431087. DOI: 10.3390/diseases12090203.


Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials.

Muthoka E, Usmael K, Embaye S, Abebe A, Mesfin T, Kazembe D Malar J. 2023; 22(1):320.

PMID: 37865784 PMC: 10590517. DOI: 10.1186/s12936-023-04757-2.


Variations in the use of malaria preventive measures among pregnant women in Guinea: a secondary analysis of the 2012 and 2018 demographic and health surveys.

Barry I, Toure A, Sangho O, Beavogui A, Cisse D, Diallo A Malar J. 2022; 21(1):309.

PMID: 36316702 PMC: 9623996. DOI: 10.1186/s12936-022-04322-3.


Factors influencing health workers' compliance with the WHO intermittent preventive treatment for malaria in pregnancy recommendations in the Northern Region, Ghana.

Mohammed A, Duah D, Kenu E, Nonvignon J, Manu A, Bonful H Malar J. 2022; 21(1):273.

PMID: 36153616 PMC: 9509592. DOI: 10.1186/s12936-022-04286-4.


The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria.

Andronescu L, Sharma A, Peterson I, Kachingwe M, Kachepa W, Liang Y J Infect Dis. 2021; 225(2):248-256.

PMID: 34216212 PMC: 8763957. DOI: 10.1093/infdis/jiab351.


References
1.
GILLES H, Lawson J, Sibelas M, Voller A, Allan N . Malaria, anaemia and pregnancy. Ann Trop Med Parasitol. 1969; 63(2):245-63. DOI: 10.1080/00034983.1969.11686625. View

2.
Brabin L, Brabin B, VAN DER KAAY H . High and low spleen rates distinguish two populations of women living under the same malaria endemic conditions in Madang, Papua, New Guinea. Trans R Soc Trop Med Hyg. 1988; 82(5):671-6. DOI: 10.1016/0035-9203(88)90191-5. View

3.
Parise M, Ayisi J, Nahlen B, Schultz L, Roberts J, Misore A . Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998; 59(5):813-22. DOI: 10.4269/ajtmh.1998.59.813. View

4.
Harrington W, Mutabingwa T, Kabyemela E, Fried M, Duffy P . Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011; 53(3):224-30. PMC: 3202321. DOI: 10.1093/cid/cir376. View

5.
Nkhoma S, Molyneux M, Ward S . Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi. Acta Trop. 2007; 102(2):138-42. DOI: 10.1016/j.actatropica.2007.04.006. View